Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage pharmaceutical company whose news flow centers on the development of next-generation pain and central nervous system therapeutics that incorporate built-in abuse and overdose protection. Company updates frequently highlight progress across its proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) platforms, which are designed to create tamper-resistant prodrugs and overdose-protected medications.
Investors and healthcare observers following ENSC news can expect regular coverage of clinical milestones for PF614, the company’s TAAP™ extended-release oxycodone analogue for moderate to severe pain, including pivotal Phase 3 trial activities and regulatory interactions with the U.S. Food and Drug Administration. News items also describe the evolution of PF614-MPAR, which combines PF614 with MPAR® overdose protection and is advancing under FDA Breakthrough Therapy designation with support from multi-year NIDA grants.
Beyond pain management, Ensysce news includes developments in its ADHD pipeline, such as patent notices for PF8026, an immediate-release amphetamine prodrug that uses TAAP™ and MPAR® technologies to address stimulant abuse and overdose risk. Updates on PF9001, the company’s lead opioid use disorder candidate supported by a HEAL grant, also appear in the company’s communications.
Additional ENSC news covers intellectual property achievements extending MPAR® patent protection, federal grant awards, symposium presentations at major pain conferences, and financing transactions such as preferred stock offerings and registered direct offerings disclosed via SEC filings and press releases. This news page aggregates these announcements so readers can track Ensysce’s clinical, regulatory, intellectual property, and capital markets developments in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced that CEO Dr. Lynn Kirkpatrick will speak at a webinar titled ‘Strategies for Achieving Regulatory Milestones Faster’ on April 19, 2023, at 11:30 am ET. The webinar will highlight the integration of Quotient Sciences in developing PF614-MPAR, a novel opioid therapeutic for chronic pain designed to minimize abuse and overdose risks. Dr. Kirkpatrick will address the potential impact of MPAR on future pain management and share insights on Ensysce's collaboration with Quotient. Ensysce is committed to developing safer prescription drugs through innovative technologies like TAAP and MPAR, which are underpinned by substantial intellectual property protections.
Ensysce Biosciences, a clinical-stage biotech company focused on enhancing drug safety, announced the availability of an updated investor presentation on its website.
The company will host a corporate update conference call today, April 11, 2023, at 11:00 AM ET. Investors can dial in using the provided numbers and access a webcast link. A playback option will be available until May 9, 2023.
Ensysce employs proprietary technologies like TAAP and MPAR to develop tamper-proof medications aimed at reducing drug abuse risks.
Forward-looking statements indicate uncertainties in clinical success and regulatory approvals, emphasizing risks in ongoing trials and potential financial constraints.
Ensysce Biosciences (NASDAQ:ENSC) has announced positive results from a study evaluating the oral human abuse potential of its drug PF614. The study demonstrated that PF614 had significantly lower 'Drug Liking' scores compared to oxycodone at various doses, indicating reduced abuse potential. Key endpoints were met, showing PF614's lower scores at p0.0001 and p=0.0025 for 'Overall Drug Liking'. This success paves the way for discussions with the to initiate phase 3 trials. CEO Lynn Kirkpatrick expressed confidence in PF614's ability to address severe pain while minimizing abuse risks.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) reported its 2022 financial results, highlighting significant clinical advancements in its PF614 and PF614-MPAR drug products aimed at improving prescription drug safety. The cash position decreased to $3.1 million by year-end, down from $12.3 million in 2021. Research and development expenses surged to $19.8 million for 2022 from $4.7 million the prior year, as Ensysce progressed towards Phase 3 trials. The net loss narrowed to $24.2 million from the previous year's $29.1 million, reflecting ongoing efforts to obtain regulatory approvals. A corporate update call is scheduled for April 11, 2023.
Ensysce Biosciences (NASDAQ:ENSC) has completed enrollment in the final stage of its Phase 1 clinical study for PF614-MPAR, an innovative opioid overdose protection product. The study aims to assess the safety and effectiveness of PF614-MPAR, designed to combat prescription drug abuse and accidental overdose. Initial findings indicate an exceptional safety profile with limited adverse events at various dose levels. The product combines PF614 with nafamostat, providing pain relief while reducing overdose risk. Data from this trial is expected in Q2 2023, potentially marking a significant advancement in pain management solutions.